Therapeutic targets for melanoma

Drugs of the Future

Volumn 33, Issue 7, 2008, Pages 615-631

  Bozzo, J ^a   Dulsat, C ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 7 HYDROXYSTAUROSPORINE; AXITINIB; BETULIC ACID; BEVACIZUMAB; CEDIRANIB; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GENISTEIN; IMATINIB; IPILIMUMAB; LENALIDOMIDE; MEVINOLIN; OBLIMERSEN; PACLITAXEL; SORAFENIB; SUNITINIB; TAMOXIFEN; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VATALANIB; VINCRISTINE; VOLOCIXIMAB; VORINOSTAT;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DRUG TARGETING; HUMAN; MELANOMA; METASTASIS INHIBITION; NONHUMAN; PROTEIN EXPRESSION; TUMOR REGRESSION;

EID: 56749179001     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.07.1236495     Document Type: Article

References (117)

1. Markovic, S.N., Erickson, L.A., Rao, R.D. et al. Malignant melanoma in the 21st century, part 1: Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007, 82(3): 364-80.
2. Giblin, A.V., Thomas, J.M. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 2007, 60(1): 32-40.
3. Chudnovsky, Y., Khavari, P.A., Adams, A.E. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005, 115(4): 813-24.
4. Gray-Schopfer, V., Wellbrock, C., Marais, R. Melanoma biology and new targeted therapy. Nature 2007, 445(7130): 851-7.
5. Abe, R., Fujita, Y., Yamagishi, S. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini-Rev Med Chem 2007, 7(6): 649-61.
6. Ribas, A. Update on immunotherapy for melanoma. J Natl Compr Cancer Netw 2006, 4(7): 687-94.
7. Basu, A., DuBois, G., Haldar, S. Posttranslational modifications of Bcl2 family members - A potential therapeutic target for human malignancy. Front Biosci 2006, 11: 1508-21.
8. Sosman, J.A., Puzanov, I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006, 12(7, Part 2): 2376s-83s.
9. Trisciuoglio, D., Desideri, M., Ciuffreda, L. et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 2005, 205(3): 414-21.
10. Knight, A.L., Di Nicolantonio, F., Whitehouse, A.P. et al. The effect of imatinib mesylate (Glivec) on human tumor-derived cells. Anti-Cancer Drugs 2006, 17(6): 649-55.
11. Chen, R., Gandhi, V., Plunkett, W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006, 66(22): 10959-66.
12. Kwon, B.S., Tan, K. B., Ni, J. et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997, 272(22): 14272-6.
13. Li, Q., Iuchi, T., Jure-Kunkel, M.N., Chang, A.E. Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci 2007, 3(7): 455-62.
14. Ju, S.A., Lee, S.C., Kwon, T.H. et al. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol 2005, 83(4): 344-51.
15. Contardi, E., Palmisano, G.L., Tazzari, P.L. et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005, 117(4): 538-50.
16. Voigt, H., Schrama, D., Eggert, A.O. et al. CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses. Clin Exp Immunol 2006, 143(1): 93-102.
17. Critchley-Thorne, R.J., Yan, N., Nacu, S., Weber, J., Holmes, S.P., Lee, P.P. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4(5): e176.
18. Adamson, A.W., Beardsley, D.I., Kim, W.J., Gao, Y., Baskaran, R., Brown, K.D. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell 2005, 16(3): 1513-26.
19. Kwak, E.L., Kim, S., Zhang, J., Cardiff, R.D., Schmidt, E.V., Haber, D.A. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res 2006, 66(4): 1923-8.
20. Papp, T., Niemetz, A., Dosdahl, N., Kumar, K., Schiffmann, D. Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines. Oncol Rep 2007, 17(1): 135-40.
21. Schwartz, G.K., Shah, M.A. Targeting the cell cycle: A new approach to cancer therapy. J Clin Oncol 2005, 23(36): 9408-21.
22. Berthet, C., Klarmann, K.D., Hilton, M.B., Suh, H.C., Keller, J.R., Kiyokawa, H., Kaldis, P. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell 2006, 10(5): 563-73.
23. Georgieva, J., Sinha, P., Schadendorf, D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 2001, 54(3): 229-35.
24. Tang, L., Li, G., Tron, V.A., Trotter, M.J., Ho, V.C. Expression of cell cycle regulators in human cutaneous malignant melanoma. Melanoma Res 1999, 9(2): 148-54.
25. Yoo, C.B., Jones, P.A. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 2006, 5(1): 37-50.
26. Stresemann, C., Brueckner, B., Musch, T., Stopper, H., Lyko, F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006, 66(5): 2794-800.
27. Gallagher, W.M., Bergin, O.E., Rafferty, M. et al. Multiple markers for melanoma progression regulated by DNA methylation: Insights from transcriptomic studies. Carcinogenesis 2005, 26(11): 1856-67.
28. Wang, S.E., Narasanna, A., Perez-Torres, M. et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10(1): 25-38.
29. Rákosy, Z., Vízkeleti, L., Ecsedi, S. et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 2007, 121(8): 1729-37.
30. Gordon-Thomson, C., Jones, J., Mason, R.S., Moore, G.P. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. Melanoma Res 2005, 15(1): 21-8.
31. Appels, N.M., Beijnen, J.H., Schellens, J.H. Development of farnesyl transferase inhibitors: A review. Oncologist 2005, 10(8): 565-78.
32. Panka, D.J., Atkins, M.B., Mier, J.W. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res 2006, 12(7, Part 2): 2371s-5s.
33. x Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., Rusnati, M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16(2): 159-78.
34. Bouleau, S., Grimal, H., Rincheval, V., Godefroy, N., Mignotte, B., Vayssière, J.L., Renaud, F. FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway. Oncogene 2005, 24(53): 7839-49.
35. Xerri, L., Battyani, Z., Grob, J.J., Parc, P., Hassoun, J., Bonerandi, J.J., Birnbaum, D. Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res 1996, 6(3): 223-30.
36. Hase, T., Kawashiri, S., Tanaka, A. et al. Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma. J Oral Pathol Med 2006, 35(3): 136-9.
37. Nakamura, T., Mochizuki, Y., Kanetake, H., Kanda, S. Signals via FGF receptor 2 regulate migration of endothelial cells. Biochem Biophys Res Commun 2001, 289(4): 801-6.
38. Srivastava, A., Ralhan, R., Kaur, J. Angiogenesis in cutaneous melanoma: Pathogenesis and clinical implications. Microsc Res Tech 2003, 60(2): 208-24.
39. Levis, M., Small, D. FLT3 tyrosine kinase inhibitors. Int J Hematol 2005, 82(2): 100-7.
40. Serve, H., Flesch, K., Serve, S., Fenski, R., Berdel, W.E. Expression and function of Flt3/flk2 in human tumor cell lines. Int J Oncol 1999, 14(4): 765-70.
41. Sherman, M., Multhoff, G. Heat shock proteins in cancer. Ann N Y Acad Sci 2007, 1113: 192-201.
42. Guzhova, I., Margulis, B. Hsp70 chaperone as a survival factor in cell pathology. Int Rev Cytol 2006, 254: 101-49.
43. Farkas, B., Hantschel, M., Magyarlaki, M. et al. Heat shock protein 70 membrane expression and melanoma-associated marker phenotype in primary and metastatic melanoma. Melanoma Res 2003,13(2): 147-52.
44. Tsutsumi, S., Neckers, L. Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 2007, 98(10): 1536-9.
45. McCarthy, M.M., Pick, E., Kluger, Y. et al. HSP90 as a marker of progression in melanoma. Ann Oncol 2008, 19(3): 590-4.
46. Nobuhisa, T., Naomoto, Y., Takaoka, M. et al. Emergence of nuclear heparanase induces differentiation of human mammary cancer cells. Biochem Biophys Res Commun 2005, 331(1): 175-80.
47. Rivera, R.S., Nagatsuka, H., Siar, C.H. et al. Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. Oncol Rep 2008, 19(3): 657-61.
48. Rodenhiser, D., Mann, M. Epigenetics and human disease: Translating basic biology into clinical applications. CMAJ 2006, 174(3): 341-8.
49. Boyle, G.M., Marlyn, A.C., Parsons, P.G. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res 2005, 18(3): 160-6.
50. Graaf, M.R., Richel, D.J., van Noorden, C.J., Guchelaar, H.J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004, 30(7): 609-41.
51. Ridley, A.J. Rho GTPases and cell migration. J Cell Sci 2001, 114(Pt. 15): 2713-22.
52. Sarrabayrouse, G., Synaeve, C., Leveque, K., Favre, G., Tilkin-Mariamé, A.F. Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. Neoplasia 2007, 9(12): 1078-90.
53. Bähr, C., Groner, B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005, 23(1): 1-14.
54. Mitsiades, C.S., Mitsiades, N. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther 2005, 5(3): 487-99.
55. Kanter-Lewensohn, L., Dricu, A., Wang, M., Wejde, J., Kiessling, R., Larsson, O. Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: A potential therapeutic target. Melanoma Res 1998, 8(5): 389-97.
56. Béliveau, A., Bérubé, M., Rousseau, A., Pelletier, G., Guérin, S.L. Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma. Invest Ophthalmol Vis Sci 2000, 41(8): 2363-72.
57. Mostafavi-Pour, Z., Askari, J.A., Parkinson, S.J., Parker, P.J., Ng, T.T., Humphries, M.J. Integrin-specific signaling pathways controlling focal adhesion formation and cell migration. J Cell Biol 2003,161(1): 155-67.
58. Bax, D.V., Bernard, S.E., Lomas, A. et al. Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alpha 5 beta 1 and alpha v beta 3 integrins. J Biol Chem 2003, 278(36): 34605-16.
59. De, S., Razorenova, O., McCabe, N.P., O'Toole, T., Qin, J., Byzova, T.V. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 2005, 102(21): 7589-94.
60. Neto, D.S., Pantaleão, L., de Sá, B.C., Landman, G. Alpha-v-beta3 integrin expression in melanocytic nevi and cutaneous melanoma. J Cutan Pathol 2007, 34(11): 851-6.
61. Dhawan, P., Richmond, A. Role of CXCL1 in tumorigenesis of melanoma. J Leukocyte Biol 2002, 72(1): 9-18.
62. Payne, A.S., Cornelius, L.A. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002,118(6): 915-22.
63. Singh, R.K., Varney, M.L. IL-8 expression in malignant melanoma: Implications in growth and metastasis. Histol Histopathol 2000, 15(3): 843-9.
64. Litz, J., Krystal, G.W. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 2006, 5(6): 1415-22.
65. Chen, J., Cárcamo, J.M., Golde, D.W. The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signaling. J Biol Chem 2006, 281(31): 22421-6.
66. Flaherty, K.T. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006, 12(7, Part 2): 2366s-70s.
67. Shaw, R.J., Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441 (7092): 424-30.
68. Petroulakis, E., Mamane, Y., Le Bacquer, O., Shahbazian, D., Sonenberg, N. mTOR signalling: Implications for cancer and anticancer therapy. Br J Cancer 2006, 94(2): 195-9.
69. Karbowniczek, M., Spittle, C.S., Morrison, T., Wu, H., Henske, E.P. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008, 128(4): 980-7.
70. Ohren, J.F., Chen, H., Pavlovsky, A. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004, 11(12): 1192-7.
71. McCubrey, J.A., Steelman, L.S., Abrams, S.L. et al. Roles of the RAF/ MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46: 249-79.
72. Hoffmann, E., Thiefes, A., Buhrow, D., Dittrich-Breiholz, O., Schneider, H., Resch, K., Kracht, M. MEK1-dependent delayed expression of Fos-related antigen-1 counteracts c-Fos and p65 NF-kappaB-mediated interleukin-8 transcription in response to cytokines or growth factors. J Biol Chem 2005, 280(10): 9706-18.
73. Kreizenbeck, G.M., Berger, A.J., Subtil, A., Rimm, D.L., Gould Rothberg, B.E. Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomark Prev 2008, 17(4): 949-58.
74. Qi, J., Wang, J., Romanyuk, O., Siu, C.H. Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell 2006, 17(3): 1261-72.
75. Derycke, L.D., Bracke, M.E. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 2004, 48(5-6): 463-76.
76. Halbleib, J.M., Nelson, W.J. Cadherins in development: Cell adhesion, sorting, and tissue morphogenesis. Genes Dev 2006, 20(23): 3199-214.
77. Ratnam, K., Low, J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007, 13(5): 1383-8.
78. Nirodi, C., NagDas, S., Gygi, S.P., Olson, G., Aebersold, R., Richmond, A. A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. J Biol Chem 2001, 276(12): 9366-74.
79. Muruganandham, M., Alfieri, A.A., Matei, C. et al. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 2005, 11(9): 3503-13.
80. Khan, J,A., Tao, X., Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 2006, 13(7): 582-8.
81. Kallergi, G., Agelaki, S., Markomanolaki, H., Georgoulias, V., Stournaras, C. Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. Cell Physiol Biochem 2007, 20(6): 977-86.
82. Kalinsky, K., Haluska, F.G. Novel inhibitors in the treatment of metastatic melanoma. Expert Rev Anticancer Ther 2007, 7(5): 715-24.
83. Kikani, C.K., Dong, L.Q., Liu, F. "New"-clear functions of PDK1: Beyond a master kinase in the cytosol? J Cell Biochem 2005, 96(6): 1157-62.
84. Feldman, R.I., Wu, J.M., Polokoff, M.A. et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2005, 280(20): 19867-74.
85. Board, R., Jayson, G.C. Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics. Drug Resist Updat 2005, 8(1-2): 75-83.
86. Haluska, F., Pemberton, T., Ibrahim, N., Kalinsky, K. The RTK/RAS/ BRAF/PI3K pathways in melanoma: Biology, small molecule inhibitors, and potential applications. Semin Oncol 2007, 34(6): 546-54.
87. Furuhashi, M., Sjöblom, T., Abramsson, A. et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004, 64(8): 2725-33.
88. Oka, M., Kikkawa, U. Protein kinase C in melanoma. Cancer Metastasis Rev 2005, 24(2): 287-300.
89. Selzer, E., Okamoto, I., Lucas, T., Kodym, R., Pehamberger, H., Jansen, B. Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage. Melanoma Res 2002, 12(3): 201-9.
90. Hoeflich, K.P., Gray, D.C., Eby, M.T. et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006, 66(2): 999-1006.
91. Iervolino, A., Iuliano, R., Trapasso, F. et al. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res 2006, 66(12): 6280-7.
92. Dragani, T.A., Peissel, B., Zanesi, N. et al. Mapping of melanoma modifier loci in RET transgenic mice. Jpn J Cancer Res 2000, 91(11): 1142-7.
93. Meyn, M.A. 3rd., Wilson, M.B., Abdi, F.A. et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006, 281(41): 30907-16.
94. Homsi, J., Cubitt, C., Daud, A. The Src signaling pathway: A potential target in melanoma and other malignancies. Expert Opin Ther Targets 2007, 11(1): 91-100.
95. Pashenkov, M., Goëss, G., Wagner, C. et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006, 24(36): 5716-24.
96. Akira, S. Toll-like receptor signaling. J Biol Chem 2003, 278(40): 38105-8.
97. Sari, L., Andricioaei, I. Rotation of DNA around intact strand in human topoisomerase I implies distinct mechanisms for positive and negative supercoil relaxation. Nucleic Acids Res 2005, 33(20): 6621-34.
98. Giles, G.I., Sharma, R.P. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem 2005, 1(4): 383-94.
99. Lynch, B.J., Komaromy-Hiller, G., Bronstein, I.B., Holden, J.A. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma. Hum Pathol 1998, 29(11): 1240-5.
100. McClendon, A.K., Rodriguez, A.C., Osheroff, N. Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: Implications for enzyme action ahead of replication forks. J Biol Chem 2005, 280(47): 39337-45.
101. Mu, X.C., Tran, T.A., Ross, J.S., Carlson, J.A. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma. J Cutan Pathol 2000, 27(5): 242-8.
102. Iyer, S., Wang, Z.G., Akhtari, M., Zhao, W., Seth, P. Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 2005, 4(3): 261-6.
103. Javelaud, D., Alexaki, V.I., Mauviel, A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 2008, 21(2): 123-32.
104. Geney, R., Chen, J., Ojima, I. Recent advances in the new generation taxane anticancer agents. Med Chem 2005, 1(2): 125-39.
105. Bergstralh, D.T., Ting, J.P. Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 2006, 32(3): 166-79.
106. Attard, G., Greystoke, A., Kaye, S., De Bono, J. Update on tubulin-binding agents. Pathol Biol 2006, 54(2): 72-84.
107. van Horssen, R., Ten Hagen, T.L., Eggermont, A.M. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006, 11(4): 397-408.
108. Lejeune, F.J., Liénard, D., Matter, M., Rüegg, C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006, 6: 6.
109. Mazurek, S., Boschek, C.B., Hugo, F., Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005, 15(4): 300-8.
110. Ugurel, S., Bell, N., Sucker, A., Zimpfer, A., Rittgen, W., Schadendorf, D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 2005, 117(5): 825-30.
111. Negroiu, G., Branza-Nichita, N., Petrescu, A.J., Dwek, R.A., Petrescu, S.M. Protein specific N-glycosylation of tyrosinase and tyrosinase-related protein-1 in B16 mouse melanoma cells. Biochem J 1999, 344(Pt. 3): 659-65.
112. Lu, F., Yan, D., Zhou, X., Hu, D.N., Qu, J. Expression of melanin-related genes in cultured adult human retinal pigment epithelium and uveal melanoma cells. Mol Vis 2007, 13: 2066-72.
113. Hicklin, D.J., Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5): 1011-27.
114. Olsson, A.K., Dimberg, A., Kreuger, J., Claesson-Welsh, L. VEGF receptor signalling - In control of vascular function. Nat Rev Mol Cell Biol 2006, 7(5): 359-71.
115. Mehnert, J.M., McCarthy, M.M., Aziz, S.A. et al. VEGF, VEGFR1, and VEGFR2 expression in melanoma. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 8520.
116. Shibuya, M., Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312(5): 549-60.
117. Favier, B., Alam, A., Barron, P. et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006, 108(4): 1243-50.